Third Quarter 2015 Financial Results

BioLight today reported operational and financial results for the third quarter ended September 30, 2015.

Operational Highlights:

  • Reported first IOPtiMate™ System sales and additional distribution agreements, both in new territories.
  • Completed enrollment into the second U.S. clinical study in which TeaRx’s effectiveness is being assessed in tears …

    Continue reading

Partnership with Axella Research for CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer

BioLight announced today that its cancer diagnostics subsidiary, Micromedic Technologies, has entered into a Collaboration Agreement with Axella Research LLC, to advance the clinical and regulatory efforts required to commercialize the CellDetect® non-invasive diagnostic test for the monitoring of bladder cancer recurrence in the United States.

Link to …

Continue reading

Joint Investment in IOPtima Subsidiary

BioLight announced today that it has entered into a joint financing agreement with two Asia-based venture capital firms, pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight’s  IOPtima Ltd. subsidiary via a private placement. The financing will help IOPtima to continue the global …

Continue reading